Novartis AG ADR (NVS)vsRhythm Pharmaceuticals Inc (RYTM)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
RYTM
Rhythm Pharmaceuticals Inc
$82.12
-2.45%
HEALTHCARE · Cap: $5.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 29767% more annual revenue ($56.67B vs $189.76M). NVS leads profitability with a 24.7% profit margin vs -103.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RYTM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Intrinsic value data unavailable for RYTM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Revenue surging 36.9% year-over-year
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
0.0% earnings growth
Elevated debt levels
Trading at 39.7x book value
ROE of -90.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : RYTM
The strongest argument for RYTM centers on Revenue Growth. Revenue growth of 36.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : RYTM
The primary concerns for RYTM are EPS Growth, Debt/Equity, Price/Book.
Key Dynamics to Monitor
NVS profiles as a value stock while RYTM is a hypergrowth play — different risk/reward profiles.
RYTM carries more volatility with a beta of 2.14 — expect wider price swings.
RYTM is growing revenue faster at 36.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rhythm Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?